Legend:
CC = Vancouver Convention Centre
F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
|
|
|
110 * !
|
Mon, 7/30/2018,
8:30 AM -
10:20 AM
|
CC-West 215/216
|
|
Assessing Treatment Effects for Life History Processes — Topic Contributed Papers
|
|
Biopharmaceutical Section, Mental Health Statistics Section, ENAR
|
|
Organizer(s): Mouna Akacha , Novartis Pharma AG
|
|
Chair(s): Mouna Akacha , Novartis Pharma AG
|
|
8:35 AM
|
Symptom Trials Vs Morbidity/Mortality Trials: Are Different Estimands Required?
Steven Snapinn, Amgen, Inc.
|
|
8:55 AM
|
Recurrent Event Estimands: With or Without Competing Terminal Event
Jiawei Wei, Novartis
|
|
9:15 AM
|
Assessment of a Treatment Effect for Recurrent Event Data in the Presence of a Terminal Event
Philip Hougaard, Lundbeck
|
|
9:35 AM
|
Comparison of Event Rates Between On- and Off-Drug Treatment Periods for a Recurrent Adverse Event
Brenda Crowe, Eli Lilly & Co.; Haoda Fu, Eli Lilly and Company; Yebin Tao, Eli Lilly and Company
|
|
9:55 AM
|
Discussant: Hsien-Ming James Hung, PhD, Food and Drug Administration
|
|
10:15 AM
|
Floor Discussion
|
